Logo image of SKYE

SKYE BIOSCIENCE INC (SKYE) Stock Fundamental Analysis

NASDAQ:SKYE - Nasdaq - US83086J2006 - Common Stock - Currency: USD

2.89  -0.54 (-15.74%)

After market: 2.98 +0.09 (+3.11%)

Fundamental Rating

3

Taking everything into account, SKYE scores 3 out of 10 in our fundamental rating. SKYE was compared to 572 industry peers in the Biotechnology industry. While SKYE has a great health rating, there are worries on its profitability. SKYE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SKYE had negative earnings in the past year.
In the past year SKYE has reported a negative cash flow from operations.
In the past 5 years SKYE reported 4 times negative net income.
In the past 5 years SKYE always reported negative operating cash flow.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -26.05%, SKYE is in the better half of the industry, outperforming 72.74% of the companies in the same industry.
Looking at the Return On Equity, with a value of -28.02%, SKYE is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -26.05%
ROE -28.02%
ROIC N/A
ROA(3y)-205.17%
ROA(5y)-161.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SKYE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, SKYE has more shares outstanding
SKYE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SKYE has a worse debt to assets ratio.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 8.76 indicates that SKYE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.76, SKYE belongs to the best of the industry, outperforming 85.49% of the companies in the same industry.
SKYE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.76
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M -15M

2.3 Liquidity

SKYE has a Current Ratio of 14.19. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
SKYE has a Current ratio of 14.19. This is amongst the best in the industry. SKYE outperforms 88.32% of its industry peers.
A Quick Ratio of 14.19 indicates that SKYE has no problem at all paying its short term obligations.
SKYE has a Quick ratio of 14.19. This is amongst the best in the industry. SKYE outperforms 88.32% of its industry peers.
Industry RankSector Rank
Current Ratio 14.19
Quick Ratio 14.19
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.35% over the past year.
EPS 1Y (TTM)90.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.74%
EPS Next 2Y33.77%
EPS Next 3Y20.03%
EPS Next 5Y8.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SKYE. In the last year negative earnings were reported.
Also next year SKYE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

SKYE's earnings are expected to grow with 20.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.77%
EPS Next 3Y20.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SKYE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SKYE BIOSCIENCE INC

NASDAQ:SKYE (2/11/2025, 8:00:01 PM)

After market: 2.98 +0.09 (+3.11%)

2.89

-0.54 (-15.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners81.1%
Inst Owner Change-86.67%
Ins Owners1.89%
Ins Owner Change-0.13%
Market Cap87.68M
Analysts83.33
Price Target18.36 (535.29%)
Short Float %6.34%
Short Ratio10.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.17%
Min EPS beat(2)-0.55%
Max EPS beat(2)60.89%
EPS beat(4)1
Avg EPS beat(4)-3.12%
Min EPS beat(4)-62.54%
Max EPS beat(4)60.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.64%
EPS NQ rev (3m)-0.65%
EPS NY rev (1m)0%
EPS NY rev (3m)11.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-0.74
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0
BVpS2.5
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.05%
ROE -28.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-205.17%
ROA(5y)-161.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1054.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.19
Quick Ratio 14.19
Altman-Z 8.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)128.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.83%
EPS Next Y83.74%
EPS Next 2Y33.77%
EPS Next 3Y20.03%
EPS Next 5Y8.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-117.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.68%
OCF growth 3YN/A
OCF growth 5YN/A